| 02nd week of 2013 patent applcation highlights part 35 |
| Patent application number | Title | Published |
|---|
| 20130011335 | Materials and Methods Related to Sodium/Potassium Adenosine Triphosphate and SRC - This invention is based in part on the elucidation of new structural conformations and functions of the sodium/potassium adenosine triphosphate synthase (Na/K ATPase), and especially elucidation of new binding sites and interactions. The present invention provides practical applications of several surprising structural and functional relationships between Na/K ATPase and compounds which interact with Na/K ATPase. Disclosure of these structures and relationships provides insight and practical solutions to chemically affecting not only the Na/K ATPase interactions, but also regulators known to be upstream and downstream. | 2013-01-10 |
| 20130011336 | IMAGING AGENTS OF FIBROTIC DISEASES - Agents and methods for imaging a cell and/or a portion of tissue characterized by fibrosis, as well as to agents and methods for determining and/or diagnosing fibrotic diseases are disclosed herein. Also disclosed herein are polymer conjugates that can include a detectable label, a retinoid and a polymer. The polymer conjugates can be used to image a portion of tissue, deliver a detectable label to a portion of tissue or a cell and/or diagnosis a condition or disease. | 2013-01-10 |
| 20130011337 | THERAPEUTIC AGENT AND DIAGNOSTIC AGENT FOR MITOCHONDRIAL DYSFUNCTION BRAIN DISEASES - To provide a therapeutic agent and a diagnostic agent for mitochondrial dysfunction brain diseases including cerebral infarction as a representative. | 2013-01-10 |
| 20130011338 | CUPREDOXIN DERIVED TRANSPORT AGENTS AND METHODS OF USE THEREOF - The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The invention further discloses methods for treating cancer and diagnosing cancer. | 2013-01-10 |
| 20130011339 | NANOPARTICLE COMPOSITIONS COMPRISING A LIPID BILAYER AND ASSOCIATED METHODS - Bilayer-nanoparticle compositions comprising a nanoparticle core and a lipid bilayer disposed around the exterior surface of the nanoparticle core are provided. In some embodiments, these bilayer-nanoparticle compositions may be dispersed in an aqueous solution. Associated methods are also provided. | 2013-01-10 |
| 20130011340 | COMPOSITIONS AND METHODS COMPRISING MAGNETIC RESONANCE CONTRAST AGENTS - The present invention relates to compositions and methods for imaging with magnetic resonance contrast agents. In particular, the present invention provides targeted contrast agents for selective imaging. | 2013-01-10 |
| 20130011341 | COMPRESSED GAS AEROSOLS WITH ENHANCED INTENSITY AND LONGEVITY OF ACTIVES - Aerosol compositions propelled by compressed gas providing enhanced intensity of one or more active components (e.g., fragrance, malodor counteractant, insecticide, disinfectant, or antimicrobial) over an extended period of time in the environment of use consistently over the life of the product. This is provided by a selected combination of spray rate and average particle size of the composition. The increased intensity over time can be further enhanced by further selection of the initial and terminal pressure under which the composition is maintained, and the pressure drop ratio, with respect to the composition product and a suitable dispensing container. | 2013-01-10 |
| 20130011342 | SURFACTANT-FREE, WATER-FREE FORMABLE COMPOSITION AND BREAKABLE FOAMS AND THEIR USES - A substantially surface active agent-free and foam adjuvant-free composition which includes a hydrophobic solvent, a wax and a propellant. A substantially surface active agent-free and foam adjuvant-free composition, further comprising, a tetracycline antibiotic, or one or More other active agents. A method of treatment, using a substantially surface active agent-free and substantially foam adjuvant-free composition. | 2013-01-10 |
| 20130011343 | CHEWING GUM HAVING SUSTAINED RELEASE OF NICOTINE - The present invention relates to a chewing gum having a high Surface Area to Volume ratio (SAV ratio), wherein said chewing gum comprises a water insoluble gum base matrix, a water soluble bulk portion and nicotine, wherein the gum base matrix, nicotine and the bulk portion are mixed and extruded to form a final extruded chewing gum product having a SAV ratio above 0.7, and wherein sustained release of nicotine is facilitated by adding 0.1-10% of C8-C10 triglycerides by weight of the chewing gum. | 2013-01-10 |
| 20130011344 | USE OF IMINOCYCLITOLS AS INHIBITORS OF BACTERIAL ADHERENCE TO EPITHELIAL CELLS - It comprises the use of D-fagomine or derivatives thereof in the prevention and/or coadjuvant treatment of bacterial infections, as well as to pharmaceutical, veterinary, or food and feed, pet food compositions containing them. | 2013-01-10 |
| 20130011345 | FLAVOR-ENHANCING AMIDE COMPOUNDS - The present invention has discovered that amide compounds represented by Formula I set forth below and isomers thereof have unexpected and advantageous flavor enhancement and modification properties: | 2013-01-10 |
| 20130011346 | Personal Care Compositions With Improved Solubility of a Solid UV Active - A personal care composition may have an isosorbide diester having the formula: | 2013-01-10 |
| 20130011347 | Personal Care Compositions With Improved Solubility of a Solid Cosmetic Active - Personal care compositions are disclosed comprising an isosorbide diester having the formula: | 2013-01-10 |
| 20130011348 | OIL-IN-WATER TYPE EMULSION SUNSCREEN COSMETIC COMPOSITION - Disclosed is an oil-in-water type emulsion sunscreen cosmetic composition which has improved ultraviolet blocking capability by containing a large amount of an ultraviolet absorbent, while having excellent emulsion stability and good usability. Specifically disclosed is an oil-in-water type emulsion sunscreen cosmetic composition which is characterized by containing (A) 1-7.5% by mass of octyl methoxycinnamate, (B) 0.5-4% by mass of t-butyl methoxybenzoyl methane and/or 2-hydroxy-4-methoxybenzophenone, (C) 0.5-3% by mass of a polyoxyethylene-polyoxyalkylene alkyl ether block polymer having a specific structure and (D) not less than 10% by mass of a nonpolar oil relative to the total amount of the oil component. The oil-in-water emulsion sunscreen cosmetic composition is also characterized by having an average emulsion particle diameter of not more than 700 nm. | 2013-01-10 |
| 20130011349 | Topical Formulations Containing Palm Pollen - Compositions are provided that include date palm pollen or an extract thereof. The compositions may be formulated for topical use in methods of treatment or prophylaxis of various skin conditions or methods to counteract the effects of skin aging. | 2013-01-10 |
| 20130011350 | METAL OXIDE PARTICLES AFTERTREATED WITH ORGANIC PHOSPHORUS COMPOUNDS - The invention relates to metal oxide particles and/or metal hydroxide particles, aftertreated with an organic phosphorus compound, process for the preparation thereof, and compositions comprising same. | 2013-01-10 |
| 20130011351 | ANTIMYCOTIC PHARMACEUTICAL COMPOSITION - In a pharmaceutical composition for external use containing a compound such as luliconazole and/or a salt thereof in an amount of 5% by mass or more, comprised is/are acetone, a polyoxyethylene alkyl (having 8 to 30 carbon atoms) ether, and/or a polyoxyethylene alkenyl (having 8 to 30 carbon atoms) ether. Provided is a preparation using a solvent other than crotamiton, propylene carbonate, and N-methyl-2-pyrrolidone as a solvent for solubilization and steric stabilization and having the following properties: 1) when a compound represented by the general formula (1) and/or a salt thereof has a stereoisomer, the amount of the stereoisomer of the compound and/or a salt thereof produced under a preservation condition of 60° C. for 3 weeks is 1% by mass or less with respect to the total mass of the compound and/or a salt thereof at the beginning of preservation; 2) the preparation is in a clear liquid state when preserved at a constant temperature of 20° C. immediately after manufacture; and 3) no crystal is deposited when the preparation is preserved at 5° C. for 2 weeks after manufacture. | 2013-01-10 |
| 20130011352 | ORGANIC CARBONATES WITH VANILLA ODOR - The invention relates to a method to confer, enhance, improve or modify the odor properties of a perfuming composition or of a perfumed article, by adding to the composition or article an effective amount of at least a compound of formula (I) | 2013-01-10 |
| 20130011353 | 2-HYDROXY-6-METHYL-HEPTANE DERIVATIVES AS PERFUMING INGREDIENTS - The invention relates to a method of use of certain derivatives of formula (I) | 2013-01-10 |
| 20130011354 | Compositions For Enhancing Hair Growth - Methods and compositions for stimulating the growth of hair are disclosed wherein emulsions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R | 2013-01-10 |
| 20130011355 | N-ACYL BASIC AMINO ACID DISPERSION - Provision of an N-acyl basic amino acid dispersion superior in dispersibility. The present invention provides a production method of an N-acyl basic amino acid dispersion having a pH of 2 to 12, comprising
| 2013-01-10 |
| 20130011356 | HAIR-BINDING PEPTIDES - Hair-binding peptides were isolated for their use in a variety of personal care formulations and applications. The isolation of hair-binding peptides was accomplished by enrichment using mRNA-display selection technology. Hair care compositions comprising peptide-based reagents prepared comprising the hair-binding peptides are also provided. | 2013-01-10 |
| 20130011357 | CONDITIONING COMPOSITION FOR HAIR - The present invention is related to aqueous conditioning composition for hair comprising at least one silicone compound with multiple quaternary ammonium groups in its molecule and at least one additional silicone compound which is different from the former one. Conditioning composition of the present invention can be in the form of a shampoo, cleansing—conditioning composition, or in the form of a conditioner used after washing hair with cleansing compositions. | 2013-01-10 |
| 20130011358 | CLEANSING COMPOSITION - The present invention is related to an aqueous cleansing composition for keratin fibres, especially human hair, comprising at least one amino acid surfactant, and a cationic polymer. Accordingly, the object of the present invention is an aqueous cleansing composition comprising at least one amino acid surfactant of the following structure | 2013-01-10 |
| 20130011359 | SOLID OR POWDER HAIR STYLING COMPOSITION - The present invention provides a solid or powder hairdressing composition comprising the following (a) ingredient and (b) ingredient: | 2013-01-10 |
| 20130011360 | COSMETIC COMPOSITION COMPRISING AT LEAST ONE ORGANIC SILICON COMPOUND, AT LEAST ONE ANIONIC SURFACTANT AND AT LEAST ONE AMINATED SILICONE AS WELL AS A METHOD EMPLOYING SAID COMPOSITION - The present disclosure relates to cosmetic compositions for washing and conditioning keratin fibers, such as human keratin fibers, for example, the hair, comprising in a cosmetically acceptable medium: i) at least one organic silicon compound chosen from silanes comprising one silicon atom and siloxanes comprising two or three silicon atoms, said organic silicon compounds having at least one basic chemical functional group and at least one group chosen from hydroxyl groups and hydrolysable groups per molecule; ii) at least one anionic surfactant; and iii) at least one aminated silicone not having a quaternary ammonium group different from the at least one organic silicon compound of part i). The present disclosure also relates to a method of cosmetic treatment of keratin fibers as well as a use employing a cosmetic composition according to the disclosure. | 2013-01-10 |
| 20130011361 | PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE - The present invention provides heterocyclic derivatives of formula (I) that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed. | 2013-01-10 |
| 20130011362 | TARGETING MONOMERS AND POLYMERS HAVING TARGETING BLOCKS - Provided herein are monomers incorporating folate or other targeting agent, polymers prepared therefrom, polymers prepared therefrom having a therapeutic agent covalently coupled thereto, as well as micelles and therapeutic compositions thereof. | 2013-01-10 |
| 20130011363 | CATIONIC BETAINE PRECURSORS TO ZWITTERIONIC BETAINES HAVING CONTROLLED BIOLOGICAL PROPERTIES - Cationic polymers hydrolyzable to zwitterionic polymers, monomers for making the cationic polymers, surfaces that include the polymers, therapeutic agent delivery systems that include the cationic polymers, methods for administering a therapeutic agent using the delivery systems, and methods for making and using the cationic polymers, monomers, surfaces, and therapeutic agent delivery systems. | 2013-01-10 |
| 20130011364 | MOLECULARLY IMPRINTED POLYMERS FOR ELIMINATING METABOLITES - The present invention relates to polymers imprinted by retention solutes, use of same as well as compositions containing same. | 2013-01-10 |
| 20130011365 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The present invention relates to tetraaza phenalen-3-one compounds which inhibit poly (ADP-ribose) polymerase (PARP) and are useful in the chemosensitization of cancer therapeutics. The induction of peripheral neuropathy is a common side-effect of many of the conventional and newer chemotherapies. The present invention further provides means to reliably prevent or cure chemotherapy-induced neuropathy. The invention also relates to the use of the disclosed PARP inhibitor compounds in enhancing the efficacy of chemotherapeutic agents such as temozolomide. The invention also relates to the use of the disclosed PARP inhibitor compounds to radio sensitize tumor cells to ionizing radiation. The invention also relates to the use of the disclosed PARP inhibitor compounds for treatment of cancers with DNA repair defects. | 2013-01-10 |
| 20130011366 | Therapeutic Agent for infections, and treatment method using the same | 2013-01-10 |
| 20130011367 | Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis - Isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, novel cis regulatory elements and methods of use thereof enabling treatment of diseases characterized by aberrant neovascularization or cell growth are disclosed. | 2013-01-10 |
| 20130011368 | Metabolically Active Micro-Organisms and Methods for Their Production - The invention relates to a preparation of metabolically active bacteria, compositions comprising such a preparation, e.g., probiotic supplements or animal feeds, and to uses thereof, for example in the treatment of diseases affecting the intestinal microbial balance. Also described are a growth substrate for microorganisms comprising a mixture of complex and simple sugars and a process for the manufacture of preparations of metabolically active microorganisms using this growth substrate. | 2013-01-10 |
| 20130011369 | Method for Prevention and Treatment of Salmonella Infection - The present invention relates to a composition comprising bacteriophage SP-1, the bacteriophage capable of destroying | 2013-01-10 |
| 20130011370 | Uniform Field Magnetization and Targeting of Therapeutic Formulations - Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Also provided are bioresorbable nanoparticles prepared without the use of organic solvents, and methods for therapeutically using such bioresorbable nanoparticles. | 2013-01-10 |
| 20130011371 | ESTABLISHMENT OF PATIENT- OR PERSON- SPECIFIC CARDIAC MYOCYTE CELL LINES FROM HUMAN INDUCED PLURIPOTENT STEM CELLS (iPSCs) - A composition and method for generating patient- or person-specific proliferative and substantially pure cardiac myocyte cell lines from pluripotent stem cells (iPSCs) is described herein. The patient-specific cardiac myocyte cell lines of the present invention find applications in research, drug screening and autologous cell-based therapy. The method of the present invention is simple and reproducible and generates cardiac myocyte cells having high purities and proliferating capacities. | 2013-01-10 |
| 20130011372 | INACTIVATED MICROORGANISMS CONTAINING DOUBLE -STRAND RNA MOLECULES (DSRNA), THEIR USE AS PESTICIDES AND METHODS FOR THEIR PREPARATION - The present invention relates to a new group of pesticides consisting of inactivated microorganisms containing double-strand RNA molecules (dsRNA), corresponding to receptor genes coupled with G proteins (GPCR) whose functioning is vital for phytophagous invertebrates (insects, mites and molluscs) or for infesting or in any case harmful organisms for the health of human beings and domestic animals, and to a method for the preparation of said microorganisms. | 2013-01-10 |
| 20130011373 | SIDE POPULATION CELLS IN CARDIAC REPAIR - It has been discovered that side-population cells induce cardiac tissue repair of infarcted myocardium. Provided herein are methods directed to treatment of cardiac injury using side-population cells. | 2013-01-10 |
| 20130011374 | GROWTH INHIBITION OF MICROORGANISMS BY LACTIC ACID BACTERIA - The present invention relates to growth inhibition of microorganisms by lactic acid bacteria. The present invention also relates to the reduction and/or treatment of food-borne pathogen infections and/or nosocomial infections. The present invention also relates to the inhibition of spoilage microorganisms in food products. The present invention further relates to the modulation of gut flora. The invention is also directed to the inhibitory potential of a whey obtained from lactic acid bacteria. | 2013-01-10 |
| 20130011375 | T CELL RECEPTORS SPECIFIC FOR IMMUNODOMINANT CTL EPITOPES OF HCV - The present invention relates generally to the field of immunology. More particularly, aspects of the invention concern the discovery of several T cell receptors (TCRs) that are specific for an immunodominant CTL epitope of hepatitis C virus (HCV). Embodiments include TCRs, DNAs encoding TCRs, methods of making TCRs, and methods of using TCRs to treat, prevent or inhibit hepatitis C virus (HCV) proliferation. | 2013-01-10 |
| 20130011376 | Methods for Enhancing Natural Killer Cell Proliferation and Activity - Methods of ex-vivo culture of natural killer (NK) cells are provided and, more particularly, methods for enhancing propagation and/or functionality of NK cells by treating the cells with a nicotinamide or other nicotinamide moiety in combination with cytokines driving NK cell proliferation. Also envisioned are compositions comprising cultured NK cells and therapeutic uses thereof. | 2013-01-10 |
| 20130011377 | COMPOSITIONS, KITS AND METHODS FOR NUTRITION SUPPLEMENTATION - The present invention relates to compositions, kits and methods for the administration of various vitamin, mineral and nutrient compositions, and in a specific embodiment, the compositions, kits and methods may utilize or include vitamin D, iodine, vitamin B1, vitamin B6, vitamin B12, vitamin B2, vitamin B9, vitamin B3, vitamin E, vitamin A, vitamin C, iron, zinc, copper, magnesium, omega 3 fatty acids and one or more pharmaceutically acceptable carriers. | 2013-01-10 |
| 20130011378 | Stable formulations of a hyaluronan-degrading enzyme - Provided are compositions that are stable formulations of a hyaluronan-degrading enzyme or are stable co-formulations of a fast-acting insulin and a hyaluronan degrading enzyme, including a recombinant human PH20 (rHuPH20). | 2013-01-10 |
| 20130011379 | Pyridoxamine for the Treatment of Diabetic Kidney Disease - The present invention provides pharmaceutical compositions comprising dosage units of pyridoxamine, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, and methods for their use in limiting the progression of renal disease and/or diabetic complications in human diabetic patient. | 2013-01-10 |
| 20130011380 | Use of Cytidine Deaminase-Related Agents to Promote Demethylation and Cell Reprogramming - Methods, compositions and kits for modulating demethylation in a mammalian cell are provided. Also provided are methods, compositions and kits for screening candidate agents for activity in modulating genomic DNA demethylation in mammalian cells. These methods, compositions and kits find use in producing induced pluripotent stem cells (iPS) and somatic cells in vitro and for treating human disorders including cancer and disorders arising from defects in genomic imprinting. | 2013-01-10 |
| 20130011381 | MODIFIED ENZYME TREATMENT METHOD - Disclosed is a method for the treatment of lysosomal storage disease in mammals wherein the mammal is administered a therapeutically effective amount of an isolated, modified recombinant β-glucuronidase whereby said storage diseased disease is relieved in the brain and visceral organs of the mammal. There is also disclosed an isolated, modified recombinant β-glucuronidase wherein the modification is having its carbohydrate moieties chemically modified so as to reduce its activity with respect to mannose and mannose 6-phosphate cellular delivery system while retaining enzymatic activity. Also disclosed are other lysosomal enzymes within the scope of the invention. | 2013-01-10 |
| 20130011382 | Fibrinogen Preparations Enriched In Fibrinogen With An Extended Alpha Chain - The present invention relates to fibrinogen preparations enriched in α-extended fibrinogen. Compositions comprising such preparations show improved clotting properties compared to preparations based on HMW Fib which typically contain no or only low amounts of α-extended fibrinogen. In particular, clot formation time and the clot strength of a clot made by α-extended fibrinogen are improved. In addition, plasmin-mediated degradation of α-extended fibrinogen is reduced as compared to plasma derived fibrinogen. | 2013-01-10 |
| 20130011383 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ASTHMA - Compositions and methods for the treatment of asthma may be prepared by drilling a hole in a coconut, adding about 1/4 pound of brown sugar (piloncillo) to an inside of the coconut, plugging the hole, wrapping the coconut in plastic, and allowing the coconut water and its contents to ferment 12 inches underground for 40 days. The resulting composition may have anti-inflammatory properties that can treat inflammation and asthma in users. | 2013-01-10 |
| 20130011384 | Use of a Material, Produced from Fungal Fermentation, as a Food Supplement - The invention relates to the use of a material produced from fermentation of an organic substrate by at least one fungal microorganism belonging to the | 2013-01-10 |
| 20130011385 | TRANSPARENT BACTERIAL CELLULOSE NANOCOMPOSITE HYDROGELS - A transparent polymeric nanocomposite hydrogel is provided, wherein the polymeric nanocomposite hydrogel is made from a water insoluble polymer, i.e. poly(2-hydroxyethyl methacrylate) (PHEMA) or/and crosslinked PHEMA and a water insoluble nanofiber, i.e., bacterial cellulose (BC). Disclosed is a synthetic route for polymeric nanocomposites hydrogels. The preferred polymeric nanocompositions are produced through free radical polymerization of HEMA monomer in the presence of bacterial cellulose with an assistance of ultrasound to enhance the mixing of bacterial cellulose, initiator, and the monomers. The polymeric nanocomposite hydrogel is then formed by immersion of the dry polymeric nanocomposite in water. Disclosed is a high transmittance polymer nanocomposite hydrogel with a preferred BC loading less than 0.1%, water content of about 40% in weight, good mechanical integrity and strength. The disclosed polymer nanocomposite hydrogel and compositions pertain to hydrogel applications, particularly contact lenses and optic components for biosensor. | 2013-01-10 |
| 20130011386 | ACTIVE PROTEASE-RESISTANT ANTIBODY FC MUTANTS - The present invention relates to modified Fc-containing molecules including modified antibodies characterized by increased resistance to host and pathogen-derived proteases, ability to interact with FcγR receptors except with FcγRI, and lack of induction of IL-10 secretion by macrophages, and methods of using and making them. | 2013-01-10 |
| 20130011387 | SYSTEMS AND METHODS FOR OBTAINING IMMUNOGLOBULIN FROM BLOOD - The present disclosure relates generally to systems for obtaining a pharmaceutically acceptable immunoglobulin from blood of a donor comprising a first conduit configured to convey blood from the donor to a substrate, wherein said blood includes at least one first component and at least one second component, said first component of the blood including immunoglobulin, and wherein said substrate is adapted to bind immunoglobulin; and a second conduit configured to convey at least a portion of the second component of the blood from the first conduit to the donor. | 2013-01-10 |
| 20130011388 | INTRAVENOUS IMMUNOGLOBULIN COMPOSITION - A concentrated, immunoglobulin composition for treating subjects vaccinated against or infected with a pathogenic microorganism, is made by (a) selecting a population of individuals previously vaccinated against antigens associated with the pathogenic microorganism; (b) identifying very high titre individuals by determining the level of specific antibodies immunoreactive with the pathogenic microorganism in the blood of the individuals; (c) combining blood from the very high titre individuals; and (d) purifying and/or concentrating the product of step (c). A concentrated immunoglobulin composition can include specific antibodies immunoreactive with a pathogenic microorganism, wherein the titre of specific antibodies is at least 5 times higher than the average titre of specific antibodies of a population of individuals previously vaccinated against antigens associated with the pathogenic microorganism. The composition has a relatively high protein concentration and a low percentage of protein aggregates. The pathogenic microorganism is preferably smallpox virus or vaccinia virus. | 2013-01-10 |
| 20130011389 | COMPOSITIONS AND METHODS FOR TREATING COAGULATION RELATED DISORDERS - Disclosed are methods for preventing or treating sepsis, a sepsis-related condition or an inflammatory disease in a mammal. In one embodiment, the method includes administering to the mammal a therapeutically effective amount of at least one humanized antibody, chimeric antibody, or fragment thereof that binds specifically to tissue factor (TF) to form a complex in which factor X or factor IX binding to the complex is inhibited and the administration is sufficient to prevent or treat the sepsis in the mammal. The invention has a wide spectrum of useful applications including treating sepsis, disorders related to sepsis, and inflammatory diseases such as arthritis. | 2013-01-10 |
| 20130011390 | METHODS OF TREATING CENTRAL NERVOUS SYSTEM ISCHEMIC OR HEMORRHAGIC INJURY USING ANTI ALPHA4 INTEGRIN ANTAGONISTS - Methods of, and compositions for, treating central nervous system injury with an antagonist of an alpha4 subunit containing integrin are described. | 2013-01-10 |
| 20130011391 | ANTI-PSGL-1 ANTIBODIES AND USES THEREOF - Provided herein, in one aspect, are antibodies that immunospecifically bind to PSGL-1, polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to PSGL-1, as well as methods of treating a disorder or disease caused by or associated with increased proliferation and/or numbers of activated T cells using the antibodies described herein. | 2013-01-10 |
| 20130011392 | METHOD FOR ASSESSING THE ABILITY OF A PATIENT TO RESPOND TO OR BE SAFELY TREATED BY A NUCLEOSIDE ANALOG BASED-CHEMOTHERAPY - The invention relates to an in vitro method for determining the ability of a patient with cancer to respond to a monochemotherapy or to a polychemotherapy involving the administration of at least one chemotherapeutic agent the liver elimination of which involves cytidine deaminase (CDA), or to be treated by at least one such chemotherapeutic agent, which method comprises determining the CDA activity in a biological sample of the patient, wherein a CDA activity above 6 U/mg of serum sample total protein is indicative of the inability of the patient to respond to the chemotherapy, a CDA activity between 1.1 U/mg and 6 U/mg of serum sample total protein is indicative of the ability of the patient to be treated by the chemotherapeutic agent when said agent is administered in the context of a monochemotherapy, and a CDA activity between 1.4 U/mg and 6 U/mg of serum sample total protein is indicative of the ability of the patient to be treated by the chemotherapeutic agent when said agent is administered in the context of a polychemotherapy. | 2013-01-10 |
| 20130011393 | BAD PATHWAY GENE SIGNATURE - The invention provides materials and methods for prognosing cancer, and predicting an individual's responsiveness to cancer treatments, methods of treating cancer, and materials and methods for obtaining BAD pathway gene expression profiles useful in carrying out the methods of the invention. | 2013-01-10 |
| 20130011394 | COMPLEXES COMPRISING MHC CLASS I FUSION POLYPEPTIDES AND ANTIGEN-SPECIFIC ANTIBODIES AND METHODS OF USE - The invention comprises a complex comprising as first part an antibody derived part that specifically binds to a target antigen, and as second part a virus-derived peptide linked to a MHC class I protein complex. | 2013-01-10 |
| 20130011395 | METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASES OR CONDITIONS - The present invention relates to methods of treating immune disorders, particularly autoimmune and inflammatory disorders such as rheumatoid arthritis, and methods of producing antibodies for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies that specifically bind to NKG2D receptors present on the surface of cells underlying the disorders. | 2013-01-10 |
| 20130011396 | TREATMENT PROTOCOL - Combination treatments with an antiangiogenesis agent and non-toxic blood levels of ethanol and/or DMSO are disclosed. | 2013-01-10 |
| 20130011397 | Transforming growth factor-beta (TGF-beta) antagonists for use in treating pain - Provided herein are methods for treating pain and for reducing the excitability of nociceptors, comprising administering a TGF-β antagonist. In some embodiments, a TGF-β antagonist is a monoclonal TGF-β neutralizing antibody or a fusion product comprising a monoclonal TGF-β neutralizing antibody, a soluble receptor, an antisense oligodeoxynucleotides (ODNs), a ribozymes, a small inhibitory RNA (siRNA), Smad 6, Smad7, or a small molecule that blocks TGF-β signaling. | 2013-01-10 |
| 20130011398 | Serpin Fusion Polypeptides and Methods of Use Thereof - This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules. | 2013-01-10 |
| 20130011399 | WAP Domain Fusion Polypeptides and Methods of Use Thereof - This invention relates to fusion proteins that include a whey acidic protein (WAP) domain-containing polypeptide and a second polypeptide. Additionally, the invention relates to fusion proteins that include a WAP domain-containing polypeptide, a second polypeptide, and a third polypeptide. The second and/or third polypeptides of the fusion proteins of the invention are an Fc polypeptide; an albumin polypeptide; a cytokine targeting polypeptide; or a serpin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules. | 2013-01-10 |
| 20130011400 | Methods For Inducing Autolysis In Infectious Bacteria - The present invention relates to methods for the killing of infectious bacteria by modulating the extra-cellular concentration of bacterial cell signalling molecules. This has the effect of inducing rapid cell death (autolysis) in the majority of bacterial cells, and preventing virulence or restoring a benign state in surviving cells. These receptors have applications for the treatment of individuals with susceptibility to infection, the treatment of patients with existing infections, in disease management, and in related applications where the host for infection is an animal or plant. The compositions described herein are particularly relevant to | 2013-01-10 |
| 20130011401 | SOLUBLE PROTEINS FOR USE AS THERAPEUTICS - The present invention relates to soluble SIRPα binding proteins, for use as a medicament, in particular for the prevention or treatment of autoimmune and inflammatory disorders, for example allergic asthma and inflammatory bowel diseases. The invention more specifically relates to a soluble SIRPα binding protein comprising a complex of two heterodimers, wherein each heterodimer essentially consists of:
| 2013-01-10 |
| 20130011402 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 2013-01-10 |
| 20130011403 | KLEBSIELLA ANTIGENS - The present invention relates to an isolated nucleic acid molecule encoding an antigen, a vector comprising such nucleic acid molecule and a host cell comprising such vector. Furthermore, the invention provides antigens from | 2013-01-10 |
| 20130011404 | Methods and Compositions for Regulating Musashi Function - The invention generally features compositions and methods for detecting and regulating cell proliferation, potentiation, and differentiation in a population of cells. In particular, compositions and methods are provided for modulating the activity of Musashi proteins. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided. | 2013-01-10 |
| 20130011405 | ANTAGONIST ANTI-CD40 MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE - Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells. | 2013-01-10 |
| 20130011406 | ANTI-KIT ANTIBODIES AND USES THEREOF - Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-mediated disorder or disease and methods of diagnosing a KIT-mediated disorder or disease using the antibodies described herein. | 2013-01-10 |
| 20130011407 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF OSTEOARTHRITIS, AND METHOD OF PRODUCTION THEREFOR - Pharmaceutical compositions for treating or preventing diseases classified as any of grade 1 to 3 according to the ICRS classification of osteoarthritis, classified as any of grade 1 to 3 according to the Kellgren-Lawrence classification of osteoarthritis or classified as any of grade 1 to 3 according to the Outerbridge classification of osteoarthritis and methods of manufacturing same contain anti-Fas IgM antibody as an active ingredient and a pharmaceutically acceptable carrier with acidity of pharmaceutical compositions ranging from pH 4 to pH 9 to alleviate osteoarthritis symptoms by inhibiting the production of cartilage matrix degrading enzymes and by increasing the production of cartilage matrix. | 2013-01-10 |
| 20130011408 | Epidermal Growth Factor Receptor (EGFR) Protein SRM Assay - The current disclosure provides for specific peptides from the Epidermal Growth Factor Receptor (EGFR) protein and the derived ionization characteristics of those peptides that are advantageous for quantifying the EGFR directly in formalin fixed biological samples by the method of Selected Reaction Monitoring (SRM) mass spectrometry. Such fixed biological samples include: formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and formalin fixed and paraffin embedded tissue culture cells. EGFR protein is quantitated in biological samples by the method of SRM/MRM mass spectrometry by quantitating one or more of the peptides described herein. The peptides can be quantitated if they reside in a modified or an unmodified form. Examples of potentially modified forms of an EGFR peptides include those bearing phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence. | 2013-01-10 |
| 20130011409 | Compositions, Kits, and Methods for the Diagnosis, Prognosis, Monitoring, Treatment and Modulation of Post-Transplant Lymphoproliferative Disorders and Hypoxia Associated Angiogenesis Disorders Using Galectin-1 - The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. | 2013-01-10 |
| 20130011410 | Egg White Antibodies for Prevention and Treatment of Specific Localized Intestinal Infections and Diseases Associated with a Pathogenic Organism or Molecule - The present invention provides the method for prevention and treatment of specific localized intestinal infections and diseases using IgA and IgM antibodies obtained from the eggs of hens which have been hyperimmunized to the same specific infections and diseases. The invention describes the high functionality of IgA and IgM antibodies present in the white of an egg from a hyperimmunized chicken as compared to the IgY from the same egg. The invention also describes the resistance of IgA and IgM to low pH environments such as stomach acids. The invention also describes the inhibition of bacterial growth when bacteria are exposed to IgA antibodies specific to said bacteria together with lysozyme from egg whites. | 2013-01-10 |
| 20130011411 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS, AND TREATMENT OF CANCER - Methods and compositions for diagnosing and treating cancer, such as breast cancer are provided. In particular, methods and compositions relating to nucleic acids encoding DACH1 and DACH1 proteins are provided. | 2013-01-10 |
| 20130011412 | ANTIBODIES TO LYMPHOTOXIN-ALPHA - The invention provides various antibodies that bind to lymphotoxin-α, methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, an autoimmune disorder. The antibodies include murine, chimeric, and humanized antibodies. | 2013-01-10 |
| 20130011413 | Method and Pharmaceutical Composition for Treatment of Intestinal Disease - Provided is a pharmaceutical composition for the treatment of intestinal disease which contains an inhibitor of inflammatory cytokine IL-1 family molecules and IL-17 family molecules, and in particular contains an IL-17F inhibitor. Also provided is a pharmaceutical composition for the treatment of intestinal disease which contains an IL-17F inhibitor and an IL-17A (IL-17) inhibitor. Inflammatory cytokine IL-1 family molecules and IL-17 family molecules promote tumorigenesis during onset of colorectal cancer, and it has been found that tumorigenesis can be suppressed by suppressing these cytokines. | 2013-01-10 |
| 20130011414 | BROADLY CROSS-REACTIVE HIV-1-SPECIFIC ANTIBODIES FOR PREVENTION AND TREATMENT OF HIV - Provided herein are HIV-1-specific transforming antibodies (tAbs) and antigens that are recognized by HIV-1-specific tAbs. Also provided herein are methods for screening and/or generating HIV-1-specific tAbs and uses of tAbs for prevention and treatment of HIV-1 infection. | 2013-01-10 |
| 20130011415 | MILK DERIVED ANTIGEN SPECIFIC ANTIBODIES FOR INDUCING AN ADAPTIVE IMMUNE RESPONSE, METHODS OF PREPARATION AND USES THEREOF - The invention relates to the field of antibodies. In particular the invention relates to milk-derived antigen specific antibodies for generating an adaptive immune response, methods of preparation, and uses thereof. | 2013-01-10 |
| 20130011416 | INJECTABLE SOLUTION CONTAINING THERAPEUTIC AGENT FOR OSTEOARTHRITIS - Injections for treating and preventing diseases classified as any of grade 1 to 3 according to the ICRS classification of osteoarthritis, diseases classified as any of grade 1 to 3 according to the Kellgren-Lawrence classification of osteoarthritis or diseases classified as any of grade 1 to 3 according to the Outerbridge classification of osteoarthritis contain anti-Fas IgM antibody as an active ingredient and a pharmaceutically acceptable carrier to alleviate osteoarthritis symptoms by inhibiting the production of cartilage matrix degrading enzymes and by increasing the production of cartilage matrix. | 2013-01-10 |
| 20130011417 | COLCHICINE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, METHOD FOR PREPARING SAID DERIVATIVES, AND PHARMACEUTICAL COMPOSITION COMPRISING SAID DERIVATIVES - The present invention relates to colchicine derivatives expressed in chemical formula 1, or to pharmaceutically acceptable salts thereof, to a method for preparing said derivatives, and to a pharmaceutical composition comprising said derivatives. The colchicine derivatives according to the present invention exhibit superior immunomodulatory effects as compared with conventional immunomodulators or colchicines, and therefore can be valuably used as an immunomodulator for modulating an acute or chronic immune response in organ transplantation. | 2013-01-10 |
| 20130011418 | Antibody-Drug Conjugates - Disclosed are anti-5T4 antibody drug conjugates and methods for preparing and using the same. | 2013-01-10 |
| 20130011419 | CROSS-LINKERS AND THEIR USES - Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same. | 2013-01-10 |
| 20130011420 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION - The present invention provides antisense antiviral compounds, compositions, and methods of their use and production, mainly for inhibiting the replication of viruses of the Filoviridae family, including Ebola and Marburg viruses. The compounds, compositions, and methods also relate to the treatment of viral infections in mammals including primates by Ebola and Marburg viruses. The antisense antiviral compounds include phosphorodiamidate morpholino oligonucleotides (PMOplus) having a nuclease resistant backbone, about 15-40 nucleotide bases, at least two but typically no more than half piperazine-containing intersubunit linkages, and a targeting sequence that is targeted against the AUG start site region of Ebola virus VP35, Ebola virus VP24, Marburg virus VP24, or Marburg virus NP, including combinations and mixtures thereof | 2013-01-10 |
| 20130011421 | TRITERPENE SAPONINS, METHODS OF SYNTHESIS, AND USES THEREOF - The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation. | 2013-01-10 |
| 20130011422 | Tumor Antigens for the Prevention and/or Treatment of Cancer - The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer. | 2013-01-10 |
| 20130011423 | METALLOPROTEINASE OLIGOPEPTIDES AND THEIR THERAPEUTIC USE - The invention discloses identification and therapeutic use of matrix metalloproteinase oligopeptides, SEQID 5-SEQID 21. These oligopeptides are bound to antibodies to create an immune response in the subject mammal against the matrix metalloproteinases of various diseases. This is a means of therapeutic intervention against the disease spread created by the matrix metalloproteinases. Further use of these oligopeptide-antibody responses can be extended to any and all diseases that use the matrix metalloproteinases to aid in their pathogenicity. | 2013-01-10 |
| 20130011424 | POLYEPITOPE CONSTRUCTS AND METHODS FOR THEIR PREPARATION AND USE - The invention relates to immunogenic polyepitope constructs containing CTL and/or Th epitopes and optimized spacer sequences which improve processing and presentation of the epitopes leading to induction of high level of both CD4+ and CD8+ specific T-cell responses and specific types of cytokines, and high level of protection and therapeutic activity. | 2013-01-10 |
| 20130011425 | RAPID, EFFICIENT PURIFICATION OF HSV-SPECIFIC T-LYMPHOCYTES AND HSV ANTIGENS IDENTIFIED VIA SAME - Described is a method of identifying an immunologically active antigen of a virus that attacks skin, as well as a method of enriching a population of lymphocytes for T lymphocytes that are specific to a virus that attacks skin. Also provided are HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection that have been identified via the methods of the invention. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection. | 2013-01-10 |
| 20130011426 | Recombinant Vaccines and Use Thereof - The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule. | 2013-01-10 |
| 20130011427 | FLAVIVIRUS SPECIES-SPECIFIC PEPTIDE TAGS FOR VACCINE AND DIAGNOSTIC USE - Flaviviruses represent an increasing global public health issue, with no prophylactic and therapeutic formulations currently available for many of them. The combination of factors such as evolutionary change, global warming and wide range of animal hosts suggest the possible occurrence of | 2013-01-10 |
| 20130011428 | NOVEL STREPTOCOCCUS PNEUMONIAE OPEN READING FRAMES ENCODING POLYPEPTIDE ANTIGENS AND USES THEREOF - The present invention relates to newly identified open reading frames comprised within the genomic nucleotide sequence of | 2013-01-10 |
| 20130011429 | IMMUNOGENIC COMPOSITION - Immunogenic compositions and methods of their use, as well as processes for their production are provided herein. | 2013-01-10 |
| 20130011430 | HUMAN CHORIONIC GONADOTROPIN (hCG) BASED VACCINE FOR PREVENTION AND TREATMENT OF CANCER - The present invention is directed to a vaccine and a pharmaceutical composition comprising hCG and | 2013-01-10 |
| 20130011431 | Composition Comprising the Amyloid Beta 1-6 Peptide Coupled to a Virus-Like Particle and an Adjuvant - The present invention relates to compositions comprising a construct comprising the Aβ1-6 peptide and a pharmaceutically acceptable adjuvant, for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type. In one embodiment, the construct containing the Aβ1-6 peptide consists of a virus-like particle (VLP) of the RNA bacteriophage Qβ chemically coupled to said Aβ1-6 peptide. | 2013-01-10 |
| 20130011432 | DISRUPTED ADENOVIRUS-BASED VACCINE AGAINST DRUGS OF ABUSE - The invention is directed to an adenovirus-antigen conjugate comprising (a) a disrupted adenovirus with a coat protein and (b) an antigen conjugated to the coat protein of the disrupted adenovirus, as well as a conjugate comprising (a) a disrupted adenovirus with a coat protein and (b) an antigen conjugated to the coat protein of the disrupted adenovirus. The invention also provides a method of inducing an immune response against an antigen in a human using the aforementioned conjugates. The invention further provides an adeno-associated viral vector comprising a nucleic acid sequence which encodes an antibody directed against cocaine. | 2013-01-10 |
| 20130011433 | DENGUE TETRAVALENT VACCINE CONTAINING A COMMON 30 NUCLEOTIDE DELETION IN THE 3'-UTR OF DENGUE TYPES 1, 2, 3, AND 4, OR ANTIGENIC CHIMERIC DENGUE VIRUSES 1, 2, 3, AND 4 - The invention relates to a dengue virus tetravalent vaccine containing a common | 2013-01-10 |
| 20130011434 | ADJUVANT DILUENTS FOR LIVE VACCINES FOR PIG DISEASES - A method for preparing an injectable vaccine composition intended to combat porcine reproductive and respiratory syndrome (PRRS), includes at least the step in which: a) a live vaccine is mixed extemporaneously with an adjuvant diluent (AD). The adjuvant diluent is an oil-in-water-type emulsion or an oil-in-water-type microemulsion, or an aqueous solution including water and at least one inorganic salt selected from aluminum hydroxide, cerium nitrate, zinc sulfate, colloidal iron hydroxide or calcium chloride, salts of divalent or trivalent metals or sympathomimetic compounds. | 2013-01-10 |
